By continuing to use our site, you agree to our Terms of Use and Privacy Policy. You can learn more about how we use cookies by reviewing our Privacy Policy.

I Agree

COMPANY OVERVIEW

Lumos Pharma is a clinical-stage biopharmaceutical company whose mission is to develop new therapies for people with rare diseases, prioritizing its focus where the medical need is high, and the pathophysiology is clear. We are committed to this mission and a strategy that is grounded upon time and cost-efficient drug development to deliver safe and effective therapies to patients.

Lumos Pharma’s clinical development program will initially focus on its lead product candidate LUM-201, an oral growth hormone stimulating therapeutic in clinical development for the treatment of Pediatric Growth Hormone Deficiency (PGHD). If approved by the FDA, LUM-201 would provide an alternative to the injections that current PGHD patients endure for many years of treatment.

As a key component of our mission, Lumos Pharma is actively seeking strategic partnerships to expand its portfolio of rare disease therapeutic candidates. We leverage our experience, knowledge, and stakeholder collaborations to identify and acquire or in-license novel products for development and commercialization. Driven by a sense of commitment to patients, their families, and the broader community impacted by rare diseases, we seek to be a leading provider of innovative medications that address a multitude of rare diseases.

SCIENCE

We are a skilled, management and investor team, with long-standing scientific and drug development experiences ranging from endocrinology to neurology to inborn errors of metabolism.

We are passionately driven to harness innovative science to benefit the patients and caregivers we work with every day. Our science-driven organization searches out the best and most cutting-edge technologies and collaborators to help advance our projects – no matter where in the world they are advancing medical research.

PATIENTS

Patient-focused drug development for rare diseases is the foundational focal point at Lumos Pharma. Rare disease patients and their caretakers inspire Lumos Pharma to learn as much as it can to persevere and continue to advance the development of potential therapies. For this reason, Lumos Pharma is committed to developing these therapies with the utmost urgency and care for these patients.  We hold these patients in the highest regard and value their knowledge and experiences and respect our collective partnerships. Each and every day, we remain passionately committed to understanding patient and caregiver needs and how to best address them.

 

Intuition will tell the thinking mind where to look next -Jonas Salk

MANAGEMENT

Lumos Pharma is led by an experienced management team with longstanding experience in the development and commercialization of therapies in the rare disease space. Our collective team experience ranges from developing novel therapeutics in-house to successful multi-party collaborations with academia and government scientists to advance innovative therapeutics to rare disease patients.

Rick Hawkins

Chief Executive Officer, President and Chairman

Rick Hawkins is Chief Executive Officer, President and Chairman of Lumos Pharma. Previously, Mr. Hawkins founded Pharmaco and as Chairman, President and Chief Executive Officer, he managed the growth of that organization to over 700…

READ MORE

John C. McKew, Ph.D.

Chief Operating Officer & Chief Scientific Officer

John McKew is Chief Operating Officer & Chief Scientific Officer of Lumos Pharma. Dr. McKew has twenty-seven years of experience developing novel therapeutics where he successfully advanced therapies through preclinical and into clinical development. Prior…

READ MORE

Eugene P. Kennedy, MD, FACS

Chief Medical Officer

Eugene P. Kennedy, MD, FACS, has served as Lumos Pharma and previously NewLink Genetics CMO since November 2017. Prior to that, he served as Vice President for Clinical and Medical Affairs since 2014, having joined…

READ MORE

Carl Langren

Chief Financial Officer

Carl Langren is the Chief Financial Officer of Lumos Pharma. He brings over 13 years of public company executive experience in biotechnology, including finance, federal contracting, information systems, compliance, and operations. Prior to the merger…

READ MORE

Aaron Schuchart, MBA, BBA, CPA

Chief Business Officer

Aaron Schuchart has over twenty years of experience in key leadership roles for both large multinationals and small biotech companies, including Amgen, Novartis Diagnostics/Grifols, and Coherus Biosciences. Recently, as Chief Business Officer of Aeglea BioTherapeutics, Mr. Schuchart led the…

READ MORE

Brad Powers, JD

General Counsel

Brad Powers is the General Counsel of Lumos Pharma. Prior to the merger with Lumos Pharma, he served as General Counsel at NewLink Genetics where he was directly responsible for all legal matters including corporate…

READ MORE

Lori Lawley, CPA

Senior Vice President, Finance and Corporate Controller

Lori Lawley is the Senior Vice President of Finance and Controller at Lumos Pharma. She brings over ten years of experience and accounting expertise in overseeing financial operations. Ms. Lawley is responsible for all aspects…

READ MORE

BOARD OF DIRECTORS

Rick Hawkins

Chief Executive Officer, President and Chairman

Rick Hawkins is Chief Executive Officer, President and Chairman of Lumos Pharma. Previously, Mr. Hawkins founded Pharmaco and as Chairman, President and Chief Executive Officer, he managed the growth of that organization to over 700…

READ MORE

Emmett Cunningham

Director - Blackstone Life Sciences

Emmett Cunningham, MD, PhD, is a Senior Managing Director in the Blackstone Life Sciences group, having joined Blackstone as part of its acquisition of Clarus in December of 2018. Dr. Cunningham joined Clarus in 2006…

READ MORE

Thomas A. Raffin

Board Member

Thomas A. Raffin, MD, has served as a member of NewLink Genetics’ Board (now Lumos Pharma) since 1999. Dr. Raffin has spent 30 years on the faculty at Stanford University School of Medicine, where he…

READ MORE

Kevin Lalande

Santé Ventures

Kevin Lalande, MBA, is a Co-Founder and Managing Director of Santé Ventures, a healthcare and life science venture capital firm founded in 2006 which currently manages over $500 million across three funds with 30+ portfolio…

READ MORE

Chad A. Johnson

Board Member

Chad A. Johnson, JD, has served as a member of NewLink Genetics’ Board (now Lumos Pharma) since March 2018. Mr. Johnson is currently General Counsel at Stine Seed Company. From May 2015 to April 2017,…

READ MORE

Lota S. Zoth

Board Member

Lota S. Zoth, CPA, has served as a member of NewLink Genetics’ Board (now Lumos Pharma) and Chair of our Audit Committee since November 2012. Ms. Zoth currently also serves on the Board of Directors…

READ MORE

Joe McCracken

Board Member

Dr. McCracken has more than twenty-five years of experience in the pharmaceutical and biotechnology industry. Until his retirement in 2013, he had a successful career in the industry where he held top managerial positions in…

READ MORE

CLINICAL SCIENTIFIC ADVISORY BOARD

Peter Clayton

Dr. Clayton has been a Professor of Child Health and Paediatric Endocrinology at the University of Manchester since 2001. He has authored 200 publications on the clinical and basic science aspects of pediatric endocrinology and…

READ MORE

Reiko Horikawa

Dr. Horikawa, a pediatric endocrinologist, is the Director of the Endocrinology and Metabolism Division of the Japanese National Center for Child Health and Development (NCCHD) and has been with the NCCHD since 2002. She is…

READ MORE

Ron Rosenfeld

Dr. Rosenfeld serves as Professor and Chair (emeritus) of Pediatrics, Oregon Health & Science University in addition to his role as President of STAT5, LLC.  The author of over 600 publications and eight-edited books, Rosenfeld…

READ MORE

George Werther

Professor George Werther, a pediatric endocrinologist, is Director of the Centre for Hormone Research at Murdoch Children’s Research Institute and Director of Endocrinology at the Royal Children's Hospital (RCH) in Melbourne. Werther has been involved…

READ MORE